News
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.
2d
Pharmaceutical Technology on MSNNovo Nordisk defeated in Wegovy patent dispute by Viatris
The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
11d
Zacks Investment Research on MSNNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...
Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...
India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
Semaglutide, a GLP-1R agonist developed by Denmark’s Novo Nordisk as Ozempic, initially for type 2 diabetes, and marketed ...
3don MSN
India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...
It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results